Biotechnology
Harbour BioMed Announces 2024 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...
2024-08-28 17:44
1834
Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical
SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered ...
2024-08-28 16:40
1198
GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients
PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (NASDAQ: LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research and manufacturing services, today announced that they have received approval from the Ch...
2024-08-27 22:28
1140
Keymed Biosciences Announces Interim Results for First Half of 2024
CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) * In June 2024, the long-term e...
2024-08-27 21:10
2060
YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, announced today that it has entered into an exclusive licensing agreement with Salubris Pharmaceuticals Co., Ltd. (stock code: 002294.SZ), a leadi...
2024-08-27 18:30
1153
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor
SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for "a randomized, controlled, open-label, ...
2024-08-26 22:00
1918
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright ...
2024-08-26 19:00
1013
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer
SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the "A Randomized, Open-label, Phase II...
2024-08-23 22:00
5004
CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
SEOUL, South Korea, Aug. 23, 2024 /PRNewswire/ -- CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study of oregovomab in combination with chemotherapy (paclitaxel and carboplatin)as neo-adjuvant ...
2024-08-23 20:00
4630
GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation
SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announcedChina's National Medical Products Administration has approved Dupert®（fulzerasib, GFH925/IBI351）for the treatment of patien...
2024-08-23 19:30
3882
Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)
The World's First-in-Class Intrauterine Drug-Eluting System SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval inChina (G.X.Z.Z. 20243181461) for use in patients with ...
2024-08-23 18:45
2582
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
* Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program * Aims to strengthen its oncology portfolio with a novel drug candidate for ...
2024-08-22 21:30
1984
Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer
PALO ALTO, Calif., Aug. 22, 2024 /PRNewswire/ -- I Peace, a pioneering CDMO in induced pluripotent stem (iPS) cells, and iCamuno Biotherapeutics, a biotech company developing iPS cell-based therapies, today announced a significant milestone with the dosing of the first patient in a clinical trial...
2024-08-22 21:00
1327
Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
NANTONG and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-18, one of the company's lead saRN...
2024-08-22 20:00
1588
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major milestone: the first patient has been dosed with YOLT-203, the company's cutting-edge in vivo genome editing candidate. Th...
2024-08-22 18:00
1666
WuXi Biologics Reports Solid 2024 Interim Results
Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial m anufacturing YoY growth of 11.7% Added 61 new integrated projects, including 4 from late-phase and commercial stage Client's molecule recently acquired by MNC, highlight...
2024-08-21 23:46
3013
GenScript Launches Global Philanthropy Platform: The GenTeer Program
PISCATAWAY, N.J., Aug. 20, 2024 /PRNewswire/ -- On August 19, GenScript Biotech Corporation (referred to as GenScript) officially launched the "GenTeer (GenScript Volunteer) Program," an innovative global philanthropy platform. This initiative marks a significant step for GenScript, transitioning...
2024-08-21 09:40
1564
CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)
SHANGHAI, Aug. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the completion of enrollment in the pivotal Phase II clinical tr...
2024-08-19 20:50
2146
Sanyou Bio's Innovative Intelligent Antibody Design oneClick+ Platform is Officially Launched
SHANGHAI, Aug. 15, 2024 /PRNewswire/ -- On August 16, 2024 (local time), Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of the "Sanyou Innovative Intelligent Antibody Design oneClick+ Platform." Sanyou Bio's Innovative Intelligent Antibody Design oneClick+ Platform...
2024-08-16 06:00
1584
Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program
* Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available among key distributors across the U.S. onJuly 2, 2023 * Adalimumab-aaty's inclusion creates greater accessibility to treatments for Americans with inflammatory conditions...
2024-08-13 07:46
1605
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 302 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8680
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5513
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4990
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4738
